Comparative Pharmacology
Head-to-head clinical analysis: PAVULON versus TRACRIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PAVULON versus TRACRIUM.
PAVULON vs TRACRIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of nicotinic acetylcholine receptors at the neuromuscular junction, blocking transmission of nerve impulses to skeletal muscle.
Competitive antagonist of nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine from binding and causing muscle relaxation.
0.04-0.1 mg/kg IV bolus for intubation; maintenance: 0.01-0.015 mg/kg IV every 25-60 minutes as needed or continuous IV infusion: 1-2 mcg/kg/min.
Initial: 0.3-0.6 mg/kg IV bolus. Maintenance: 0.1-0.2 mg/kg every 20-45 minutes as needed. Alternatively, continuous infusion: 0.005-0.01 mg/kg/min (5-10 mcg/kg/min).
None Documented
None Documented
Terminal elimination half-life 100-120 minutes in adults with normal renal function; prolonged in renal impairment.
Terminal elimination half-life: approximately 20 minutes (range 15-30 min). Clinically, this short half-life results in rapid spontaneous recovery after discontinuation, making it suitable for continuous infusion.
Renal 80-100% as unchanged drug and metabolites; biliary/fecal negligible (<5%).
Renal (approximately 50-60% as unchanged drug and metabolites); biliary/fecal (minor, <10%); Hofmann elimination (non-enzymatic degradation) and ester hydrolysis contribute to clearance. Total excretion is predominantly renal.
Category C
Category C
Neuromuscular Blocking Agent
Neuromuscular Blocking Agent